12 articles in this topic
Pfizer's oral JAK inhibitor demonstrated efficacy comparable to adalimumab for treating moderate to severe rheumatoid arthritis.
New research reveals how RA affects muscle biomechanics within 6 months of symptom onset, offering insights for early intervention.
Large Hong Kong registry study tracked how well patients stayed on newer JAK inhibitors versus traditional TNF blockers for RA treatment.
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
Small NIH study tests oral drug tofacitinib as potential new treatment for systemic lupus erythematosus with fewer side effects.
Small study tests whether tocilizumab can achieve faster, deeper remission in newly diagnosed rheumatoid arthritis patients.
Phase 2 trial tests novel therapy for patients who failed standard biologics and JAK inhibitors in 145-person study.
Phase 3 trial tests otilimab against standard care in 550 patients who failed previous biologics and JAK inhibitors.
Small study explores how tofacitinib may address chronic pain that persists even when inflammation is controlled in RA patients.
Researchers used blood biomarkers and machine learning to predict which expensive RA treatments work best for individual patients.
NYU study reveals how targeted immune therapy transforms inflammatory responses in rheumatoid arthritis treatment.
Study reveals how inflammation blocks growth hormone production and tests whether etanercept can restore healthy levels in women with RA.
